Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 2/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | RXRA | P19793 | 1/20 | 0.35 |
| ▸ | RXRB | P28702 | 1/20 | 0.35 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.33 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.33 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | KDM1A | O60341 | 1/20 | 0.32 |
| ▸ | HSPA5 | P11021 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL148110 | 0.94 | IDO1 (0.46) | LMNAIDO1PTGS2TP53TRPA1 | |
| SCHEMBL16810693 | 0.89 | LMNA (0.35) | LMNAIDO1PTGS2TP53RXRA | |
| SCHEMBL16961327 | 0.87 | CYP4F2 (0.48) | LMNAIDO1PTGS2RXRARXRB | |
| SCHEMBL13226845 | 0.87 | PTGS2 (0.37) | LMNAIDO1PTGS2RXRARXRB | |
| SCHEMBL7499745 | 0.84 | ACHE (0.37) | LMNAIDO1PTGS2TP53L3MBTL1 | |
| SCHEMBL22169009 | 0.83 | CA2 (0.38) | LMNAIDO1PTGS2RXRARXRB | |
| SCHEMBL9928604 | 0.83 | ALDH1A1 (0.38) | LMNAIDO1L3MBTL1TAAR1 | |
| SCHEMBL28806252 | 0.83 | PTGS2 (0.48) | LMNAPTGS2TP53RXRARXRB | |
| SCHEMBL439074 | 0.83 | PTGS2 (0.48) | LMNAPTGS2TP53RXRARXRB | |
| SCHEMBL15275552 | 0.82 | IDO1 (0.38) | LMNAIDO1PTGS2TP53L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3923365-A1 | ORGANIC ELECTROLUMINESCENCE DEVICE AND FUSED POLYCYCLIC COMPOUND FOR ORGANIC ELECTROLUMINESCENCE DEVICE | Samsung Display Co., Ltd. (KR) | 2021-12-15 | — | — | EP | disclosed |
| US-9193740-B2 | Bismacrocyclic compounds as hepatitis C virus inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2015-11-24 | — | — | US | disclosed |
| WO-2013177668-A1 | PROTEIN KINASE INHIBITORS | PHARMASCIENCE, INC. (CA) | 2013-12-05 | — | — | WO | disclosed |
| US-20110123496-A1 | BISMACROCYCLIC COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2011-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110123496-A1 | BISMACROCYCLIC COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS | PRSS1, CTSC, CES1 | LMNA 1377/4885IDO1 839/4885PTGS2 1525/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.